Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women by Esser, Mark T et al.
, He Wang
RESEARCH ARTICLE Open Access
Seroprevalence of Human Papillomavirus Types 6,
11, 16 and 18 in Chinese Women
Jia Ji1,2†, Hai-Kui Sun1†, Jennifer S Smith1* 1 , Mark T Esser3,6, Shangying Hu1, Robert G Pretorius4,
Wen Chen1, Jerome L Belinson5 and You-Lin Qiao1,7*
Abstract
Background: Human papillomavirus (HPV) seroprevalence data have not previously been reported for different
geographical regions of China. This study investigated the cross-sectional seroprevalence of antibodies to HPV 6, 11,
16, and 18 virus-like particles in Chinese women.
Methods: Population-based samples of women were enrolled from 2006 to 2007 in 3 rural and 2 urban areas of
China. Each consenting woman completed a questionnaire and provided a blood sample. Serum antibodies were
detected using a competitive Luminex immunoassay that measures antibodies to type-specific, neutralizing
epitopes on the virus-like particles.
Results: A total of 4,731 women (median age 35, age range 14-54) were included, of which 4,211 were sexually
active women (median age 37) and 520 virgins (median age 18). Low risk HPV 6 was the most common serotype
detected (7.3%), followed by HPV 16 (5.6%), HPV 11 (2.9%), and HPV 18 (1.9%). Overall HPV seroprevalence to any
type was significantly higher among sexually active women (15.8%) than virgins (2.5%) (P = 0.005). Overall
seroprevalence among sexually active women gradually increased with age. Women from rural regions had
significantly lower overall seroprevalence (Odds Ratio (OR) = 0.7; 95% CI: 0.6-0.9, versus metropolitan regions,
P< 0.001). With increasing number of sexual partners, women were at higher risk of seropositivity of any type
(OR = 2.6; 95% CI: 1.7-3.9 for > = 4 partners versus 1 partner, P< 0.001). Wives were at higher risk of seropositivity
for HPV 16/18/6/11 when reporting having a husband who had an extramarital sexual relationship (OR = 2.0; 95% CI:
1.6-2.5, versus those whose husbands having no such relationship, P< 0.001). There was a strong association
between HPV 16 seropositivity and presence of high-grade cervical lesions (OR = 6.5; 95% CI: 3.7-11.4, versus normal
cervix, P< 0.001).
Conclusions: HPV seroprevalence differed significantly by age, geography, and sexual behavior within China, which
all should be considered when implementing an optimal prophylactic HPV vaccination program in China.
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Background
The etiological role of human papillomavirus (HPV) in-
fection in cervical precancer/cancer is supported by nu-
merous biological and epidemiological studies [1-3].
Oncogenic HPV DNA has been detected in nearly all
cases of cervical cancer and 80-90% of high-grade pre-
cancerous lesions by sensitive DNA detection techniques
[4-6]. HPV 16 is the most common oncogenic type and
is detectable in approximately half of all cervical cancers
[7,8]. HPV 18 is the second most common type in inva-
sive cervical cancer world-wide [8], and in China [9].
Condylomata acuminata, also known as genital warts, is
the most common benign tumor in the anogenital tract
[10]. Together, HPV types 6 and 11 are the main causal
agents of genital warts and have been detected in up to
90% of cases [11], of which HPV 6 is approximately three
times more common [12,13].
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Recent advances in technology have improved our
ability to detect HPV cumulative exposure by measuring
the antibody response to virus-like particles. HPV DNA
is often transient in exfoliated cells or tissue and thus
cannot provide a reliable indicator of past exposure [14].
HPV DNA detection is also limited by sampling difficul-
ties because many unmarried women are unwilling to
undergo gynecologic examinations for the collection of
exfoliated cells, particularly in many regions of Asia, in-
cluding China. Although a substantial proportion
(~50%) of women exposed to specific HPV types do not
seroconvert [15], HPV antibody responses may be a use-
ful proxy marker of cumulative exposure to HPV [16].
Serological assays based on virus-like particles (VLPs)
make it possible to detect HPV antibodies likely indica-
tive of previous exposure to HPV infection. Several stud-
ies have detected antibodies to neutralizing epitopes on
virus-like particles for HPV types 6, 11, 16, and 18 using
a multiplex Luminex assay [17,18]. However, few studies
have estimated HPV seroprevalence using representative,
population based samples.
Therefore, in this report, we measured seroprevalence
of four common HPV types (6, 11, 16, and 18) in a
population-based sample of women from five regions of
Mainland China, stratified by histological grade of cer-
vical intraepithelial neoplasia (CIN). The purpose of this
study was to evaluate HPV seroprevalence and estimate
HPV cumulative exposure among Chinese women, as
well as to identify its risk factors.
Material and methods
Study population
This cross-sectional study was performed within Mainland
China between May, 2006 and April, 2007, and included
population based samples of women from 5 areas of
China: Shanxi (North, rural), Beijing (North, urban),
Xinjiang (West, rural), Henan (North, rural) and Shang-
hai (South, urban), as previously described [19]. Sub-
jects aged 14 to 54 years were eligible to participate.
Exclusion criteria consisted of women self-reporting a
hysterectomy, history of pelvic radiotherapy, or current
pregnancy. Census information was obtained for all
residents, stratified by village, commune and county in
each province. The information provided included
name, sex, date of birth and address for the women in
each village. We then obtained the numbers of women
eligible for screening in each village (“the target popula-
tion”). We recruited women with different outreach
strategies, including the utilization of booklets, notices
placed community bulletin boards, and television
announcements. Village doctors invited women to par-
ticipate by visiting each household with eligible women
in the community. Women who agreed to participate ei-
ther signed or fingerprinted the consent form. The
Institutional Review Boards of The Cleveland Clinic,
and Cancer Foundation of China approved this study as
well as the consent form.
Consenting women were enrolled in an age-stratified
quota sample, with aimed maximum of 125 women in
each of eight 5-year age strata (15-19, 20-24, 25-29, 30-
34, 35-39, 40-44, 45-49, 50-54 years) per geographic
area. We encountered difficulties, however, in recruiting
women aged 15 to 19 years, as most women in this age
group are not married and therefore not willing to
undergo gynecological examinations. Due to the rela-
tively small number of subjects in 15-19 year age group
(n = 27), we combined this group with the 20-24 age
group for data analyses.
There were 4,372 sexually active subjects according to
self-reported sexual history, who provided serum sam-
ples. Basic sociodemographic data, menstrual and repro-
ductive history, sexual history and other behavioral
information were collected during the visit when the
plasma was obtained. Additionally, 649 subjects self-
reported with no prior history of sexual intercourse were
interviewed for demographic and behavioral information.
Sample collections
Nine ml of blood was taken from all consenting females.
Blood samples were centrifuged for 10 minutes and
aliquoted into plasma, buffy coats and red blood cells.
Aliquots of blood were stored at -80° C. Consenting
sexually active women also provided self- or physician-
collected exfoliated cervical cells for HPV DNA detec-
tion by HC2 (hybrid capture II, QIAGEN Corp,
Gaithersburg, MD).
HPV DNA measurement and cytology/histology evaluation
A threshold value of at least 1.0 pg/ml was used as the
cut-off for HC2 positivity, according to the manufac-
turer’s instructions. Details on HPV DNA measurement
are previously described [20]. Liquid Based Cytology
(SurePath, Becton Dickinson, Franklin Lakes, NJ) was
performed using exfoliated cervical cells for cervical
cytological diagnoses. Women in rural areas who were
HPV positive within the self or physician obtained sam-
ples by HC2 or had low-grade squamous intraepithelial
lesion (LSIL) or greater diagnoses on cytology under-
went colposcopy with the Preventive Oncology Inter-
national (P.O.I.) microbiopsy protocol [19,21]. In urban
sites, the referral standard was (1) atypical squamous
cells of undetermined significance (ASCUS)/HPV posi-
tive or (2) LSIL or greater. Urban sites include Beijing
and Shanghai whereas rural areas refer to Xinjiang,
Henan and Shanxi. The original biopsy diagnoses made
by pathologists at CICAMS were used for data analyses.
Histology slides were reviewed by a United States panel
of experts that resulted in no major high-grade to low
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grade categorical shifts. High-grade cervical lesions were
defined as CIN2 or greater in histology or high-grade
squamous intraepithelial lesions (HSIL) in cytology.
Details on sampling and diagnosis procedure of cytology
or histology are previously described [20]. Numbers of
women diagnosed of CIN1, CIN2, CIN3, and cancer
were 114, 27, 37, and 5, respectively.
HPV antibody detection by multiplex Luminex assay
Yeast-derived VLPs were coupled to a set of four distinct
fluorescent Luminex microspheres using conjugation
chemistry as previously described [18]. Antibody titers
were determined in a competitive format in which
known, type-specific phycoerythrin (PE)-labeled, neutral-
izing monoclonal antibodies (mAbs) competed with the
subject’s serum antibodies for binding to type-specific,
conformationally sensitive, neutralizing epitopes on the
VLPs. Fluorescent signals from the bound HPV-specific
detection mAbs are inversely proportional to the sub-
ject’s neutralizing antibody titers. Results for the assay
were reported as concentration of antibody in milli-
Merck Units per milliliter (mMU/mL).
The HPV 6, 11, 16 and 18 complex Luminex immuno-
assay (cLIA) was performed in a 96-well microtiter plate.
Samples were tested at a 1:4 dilution. Serum samples
and detection antibodies were added to each well, fol-
lowed by the VLP-microspheres for types 6, 11, 16 and
18. The plates were sealed with foil covers and incubated
overnight for 15 to 25 hours. Following incubation, the
plates were washed 3 times and then analyzed on a Bio-
Plex (Luminex) instrument. High, medium, low and
negative controls used for this assay were collected from
humans that were either HPV sero-negative, had low
antibody titers from natural infection or had medium to
high antibody titers to HPV L1 VLPs following vaccin-
ation. Details of cLIA are described elsewhere [17,18].
Statistical analysis
The statistical database was created using Microsoft
Visual FoxPro (version 8.0). Odds ratios (OR) for HPV
seropositivity and corresponding 95% confidence inter-
vals (CI) were calculated by non-conditional logistic re-
gression, with adjustment for age (15-24, 25-34, 35-44,
45-54 years), geographic site (Beijing, Shanghai,
Xinjiang, Henan and Shanxi) and HPV HC2 DNA status.
The adjustment over HPV DNA status considers poten-
tial association between HPV serology and HPV DNA
results. Chi-square test was conducted at significance
level of 0.01. Basic statistical analyses were conducted
using STATA (version 9.0) and R (version 2.4.0).
Among 4,372 sexually active subjects, 4,212 women
had finished questionnaire and complete HPV DNA data
and cytology results. One woman had missing sero-
logical result and was therefore not included in the
analysis. Thus 4,211 women (age 17-54, median 37) were
included for final statistical analyses (i.e. risk factor ana-
lyses) restricted to sexually active women. Of 649 vir-
gins, 520 subjects (age 14-36, median 18) provided
blood samples and had serological results available for
analyses.
Results
Overall seroprevalence
A total of 4,731 participating females had HPV serology
results measured and validated by serology assay and
completed questionnaire information with a median age
of 35 (range 14-54 years). Overall, oncogenic HPV 16
seroprevalence was higher (5.6%; 95% CI: 5.0-6.3%) than
that of HPV 18 seroprevalence (1.9%; 95% CI: 1.5-2.3%).
Low risk HPV 6 was the most common serotype
detected (7.3%; 95% CI: 6.6-8.0%), and notably more
common than HPV 11 (2.9%; 95% CI: 2.4-3.4%,
P< 0.001) (Figure 1). For both sexually active and
women who reported being virgins, HPV 6 was the most
common HPV serotype detected, followed by HPV 16,
HPV 11 and HPV 18. HPV seroprevalence was signifi-
cantly higher among sexually active women than virgins
for seropositivity to any type (15.8% versus 2.5%,
P = 0.005), as well as each individual HPV type tested. Of
note, seroprevalence of HPV 6 among virgins was 1.9%
(95% CI: 0.7-3.1%).
Seroprevalence and its risk factors in sexually active
women
Among 4,211 sexually active women, women recruited
in Xinjiang area are from Uyghur ethnic group, whereas
other areas represent the majority Han ethnic group.
One third of women had elementary or lower education
(32.2%), while most were married (94.8%), never smo-
kers (96.9%), never drinkers (79.4%), and reported a his-
tory of contraceptive method use (89.5%). Most women
(79.9%) had started their sexual life before 25 years of
age, and reported a single lifetime sexual partner
(77.3%).
Overall and type-specific HPV 6, 11, 16 and 18 sero-
prevalence limited to 4,211 sexually active women are
shown in Figure 2. HPV 16 seroprevalence increased
from 4.9% in younger women (<30 years) to 6.7%
among women over 30 years of age. Age-specific sero-
prevalence of HPV 18 was consistently the lowest across
different age groups (range 1.3-2.9%). HPV-6 seropreva-
lence was the most common type, characterized by a
plateau (7.5–7.8%) under 40 and a peak (9.8%) among
women in their late forties, with decreased seropreva-
lence in women aged above 50. HPV 11 seroprevalence
ranged from 2.2% to 3.9%. Overall seroprevalence in
Chinese women increased gradually with age, with a
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peak (19.0%) in the 45-49 age group, with lower percent-
age of seropositive women older than 49.
In terms of sociodemographic and sexual risk factors
for type-specific HPV seropositivity, females over 35
years old had a higher seroprevalence of HPV 6/11/16/
18 (OR= 1.3 [95% CI: 1.0-1.8] versus 15-24 years after
controlling for geographic site and HPV DNA positivity)
(Table 1). Women from rural regions had a significantly
lower seropositivity for HPV 6/11/16/18 (OR= 0.7; 95%
CI: 0.6-0.9, P< 0.001) compared with women from
metropolitan areas. Women living in Shanghai had sig-
nificantly higher seropositivity of any type as compared
with women from other four sites (OR= 1.6; 95% CI:
1.2-2.0 versus Beijing, P< 0.001). Women reporting a
higher number of sexual partners were at a higher risk
of HPV 6/11/16/18 seropositivity (OR= 2.6 [95% CI: 1.7-
3.9] for ≥ 4 versus 1 partner). Wives were at higher risk
of exposure to HPV of all types when they reported their
husband had extramarital sexual relationships (OR= 2.0;
95% CI: 1.6-2.5). There was no difference in seropositiv-
ity for HPV 6/11/16/18 with respect to women’s
reported education level, marital status, smoking or
drinking habits, parity, age at first menstruation or
sexual intercourse, or contraceptive use.
A trend of higher type-specific seropositivity with
increasing age was observed for HPV-6 or 16, although
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Figure 2 Age–specific HPV 6, 11, 16 and/or 18 seroprevalence in 4211 sexually active women from five geographic areas in China.
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Figure 1 Seropositivity of anti-HPV 16, 18, 6, 11, 16 or 18, 6 or 11, and any of four types in sexually active women (n= 4211), virgins
(n = 520) and total women (n = 4731) from five geographic areas in China.
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Table 1 Odds ratios (ORs) and 95% confidence intervals (CIs) for HPV seropositivity according to sociodemographic
and related variables (n =4211)
Anti-HPV
6/11/16/18
Anti-HPV 6 Anti-HPV 16
Variable Categories n % ORa
(95% CI)
% ORa
(95% CI)
% ORa
(95% CI)
Sociodemographic characteristics
Age (years) 15-24 484 13.0 1.0 7.6 1.0 4.3 1.0
25-34 1241 14.5 1.1 (0.8-1.6) 7.7 1.1 (0.7-1.6) 6.3 1.5 (0.9-2.5)
35-44 1252 17.3 1.3 (1.0-1.8) 8.4 1.1 (0.8-1.7) 6.9 1.5 (0.9-2.5)
45-54 1234 16.7 1.3 (1.0-1.8) 7.9 1.1 (0.7-1.6) 6.4 1.5 (0.9-2.5)
Race Han Ethic Group 3328 16.2 1.0 7.5 1.0 6.8 1.0
Uyghur Ethnic Group 883 14.4 1.0 (0.8-1.2) 9.5 1.4 (1.1-1.8) 4.3 0.7 (0.5-1.1)
Region Metropolitan 1566 18.6 1.0 7.7 1.0 7.7 1.0
Rural 1762 14.0 0.7 (0.6-0.9) 7.4 1.0 (0.7-1.3) 6.0 0.8 (0.6-1.1)
Geographic Site Beijing 792 15.3 1.0 6.2 1.0 5.4 1.0
Shanghai 774 22.1 1.6 (1.2-2.0) 9.3 1.5 (1.1-2.3) 9.9 1.9 (1.3-2.8)
Xinjiang 883 14.4 1.1 (0.8-1.4) 9.5 1.7 (1.2-2.5) 4.3 1.0 (0.6-1.5)
Henan 878 13.0 0.9 (0.7-1.2) 7.4 1.3 (0.9-1.8) 5.1 1.0 (0.7-1.6)
Shanxi 884 14.9 1.0 (0.7-1.3) 7.4 1.2 (0.8-1.8) 6.9 1.3 (0.9-2.0)
Education level Primary School or Lower (0-6 year) 1352 14.1 1.0 8.7 1.0 4.4 1.0
Secondary School or Higher
(>= 7 year)
2851 16.5 1.0 (0.8-1.3) 7.5 0.9 (0.7-1.2) 7.1 1.4 (1.0-1.9)
Marital status Single 34 26.5 1.0 8.8 1.0 8.8 1.0
Married 3990 15.2 0.5 (0.2-1.1) 7.6 0.7 (0.2-2.5) 6.1 0.6 (0.2-2.1)
Widowed/Separated/Divorced 185 26.0 0.8 (0.3-1.9) 15.1 1.4 (0.4-5.3) 9.7 0.8 (0.2-3.3)
Lifestyle characteristics
Smoking Never Smoked 4078 15.6 1.0 7.8 1.0 6.3 1.0
Former/Current Smoker 131 19.9 1.2 (0.7-1.8) 12.2 1.6 (0.9-2.8) 6.1 0.8 (0.4-1.7)
Drinking Never 3204 15.8 1.0 7.9 1.0 6.3 1.0
Ever 832 16.5 1.0 (0.8-1.3) 8.4 1.2 (0.9-1.6) 6.6 1.0 (0.7-1.4)
Menstrual and reproductive characteristics
Age at first menstruation <=13 1042 14.9 1.0 8.0 1.0 5.6 1.0
14-16 2468 15.8 1.1 (0.9-1.4) 7.8 0.9 (0.7-1.2) 6.4 1.3 (0.9-1.8)
>= 17 697 17.2 1.2 (0.9-1.6) 8.6 1.0 (0.7-1.4) 6.9 1.3 (0.9-2.0)
Number of Pregnancies 0 155 14.2 1.0 9.7 1.0 3.9 1.0
1 785 15.0 1.0 (0.6-1.7) 7.3 0.7 (0.4-1.3) 5.7 1.4 (0.6-3.3)
2 1196 15.6 1.0 (0.6-1.6) 7.2 0.7 (0.4-1.3) 6.6 1.4 (0.6-3.4)
3 or more 2051 16.3 1.1 (0.7-1.8) 8.5 0.8 (0.4-1.4) 6.5 1.6 (0.7-3.8)
Abortion spontaneous only 356 13.5 1.0 7.0 1.0 4.8 1.0
voluntary only 1879 17.8 1.3 (0.9-1.8) 8.2 1.3 (0.8-2.0) 8.0 1.7 (1.0-2.9)
both 271 15.9 1.2 (0.8-1.9) 9.6 1.4 (0.8-2.5) 4.4 1.0 (0.5-2.1)
Sexual characteristics
Age at first sexual intercourse <20 1249 14.7 1.0 8.7 1.0 5.2 1.0
20-24 2112 15.8 1.0 (0.8-1.3) 8.1 1.1 (0.8-1.6) 6.6 1.0 (0.6-1.4)
>= 25 844 17.3 0.9 (0.6-1.2) 6.4 0.7 (0.5-1.2) 7.0 0.8 (0.5-1.4)
Ever used contraceptive measures No 435 17.2 1.0 10.3 1.0 6.9 1.0
Yes 3711 15.7 0.9 (0.6-1.1) 7.7 0.8 (0.5-1.1) 6.2 0.8 (0.5-1.2)
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results were imprecise. There were ethnic group or
regional differences in seropositivity for HPV 6 antigen
(OR= 1.4, 95% CI: 1.1-1.8, Uyghur minority versus Han
majority group; OR= 1.5, 95% CI: 1.1-2.3, Shanghai ver-
sus Beijing). A significant increase in seropositivity for
HPV 6 or 16 was observed in women reporting having
more than one lifetime sexual partner or their husband
having had extramarital sexual relationships (P< 0.001).
Other factors were not found to be significantly asso-
ciated with seropositivity for HPV 6 or 16 among
Chinese women.
Seroprevalence and cytology/histology
Table 2 reports HPV 6/11/16/18 seroprevalence collect-
ively, and by HPV type for women with a diagnosis of
normal cytology or CIN. In women with high-grade cer-
vical lesions, the percentage of seropositive women to
HPV 6/11/16/18 was significantly higher than among
women with a diagnosis of normal histology (OR= 4.0
for CIN2 or above; 95% CI: 2.4-6.8, P< 0.001), or nor-
mal cytology (OR= 4.2; 95% CI: 2.4-7.3, P< 0.001). This
significance was primarily from HPV 16 (OR=6.5 [95%
CI: 3.7-11.4] for CIN2 or above by pathology, P< 0.001;
OR= 6.2 [95% CI: 3.4-11.4] by cytology versus normal
diagnosis, P< 0.001). The percentage of seropositive
samples for HPV 11 was significantly higher in women
with HSIL or above by cytology (OR= 4.1; 95% CI: 1.7-
10.1, P< 0.001), but not in women with CIN2 or above
by pathology grading. Significant difference was not seen
for anti-HPV 18 or 6 in regards to pathology or cytology
grading.
Discussion
This report of population-based seroprevalence of HPV
among Chinese women, to our knowledge, is the first to
be conducted. Within five different geographic regions
across Western to Eastern China, we found a higher
HPV seroprevalence in women from metropolitan areas,
Uyghur ethnic groups, and in Shanghai city. Differences
in sexual behavior, as well as differences in underlying
population-based seroprevalence, are likely causes of dif-
ferences in HPV seropositivity across regions. Overall
seroprevalence of HPV 6, 11, 16 and 18 among Chinese
women increased with age, and were strongly correlated
with higher grades of cervical lesions.
A relatively low seroprevalence to HPV 16 and 18 was
found among Chinese females, as compared to other
areas worldwide [22]. Given the large population base
and relatively conservative sexual behavior among
women in China within the past few decades, prevalence
of serological responses to HPV is, as expected, to be
low as compared to a relatively wide range of seropreva-
lence observed globally. Regarding Asia, HPV 16 and 18
seroprevalence in our study is most comparable to a
population-based study in Taiwan (6.3% vs. 7.6%, 2.1%
vs. 3.9%, respectively) [23], but much lower than that
Table 1 Odds ratios (ORs) and 95% confidence intervals (CIs) for HPV seropositivity according to sociodemographic
and related variables (n =4211) (Continued)
Lifetime no. sex partners 1 3230 13.5 1.0 6.7 1.0 4.9 1.0
2 634 23.3 2.0 (1.6-2.4) 11.7 1.7 (1.3-2.3) 11.7 2.6 (1.9-3.5)
3 194 21.1 1.7 (1.2-2.5) 12.4 1.8 (1.1-2.8) 7.7 1.7 (0.9-3.0)
>= 4 123 28.5 2.6 (1.7-3.9) 13.8 2.0 (1.2-3.4) 11.4 2.7 (1.5-5.0)
Husband's extramarital sexual relationships No 2044 13.4 1.0 6.6 1.0 4.8 1.0
Yes 856 22.7 2.0 (1.6-2.5) 12.4 1.8 (1.4-2.4) 9.1 2.2 (1.6-3.0)
Unknown 1526 15.5 1.3 (1.0-1.5) 7.5 1.1 (0.8-1.4) 6.9 1.6 (1.2-2.1)
aOR: adjusted for age, geographic site and HPV DNA positivity on each variable, with exception on age variable with OR adjusted for geographic site and HPV
DNA positivity, and on race, region, and geographic site variable with OR adjusted for age and HPV DNA positivity.
Table 2 Anti-HPV 16, 18 or 6/11/16/18 serological responses, stratified by cytological and histological diagnoses
(n =4211)
Anti-HPV 6/11/16/18 Anti-HPV 16 Anti-HPV 18 Anti-HPV 6 Anti-HPV 11
Histology n % ORa (95% CI) % ORa (95% CI) % ORa (95% CI) % ORa (95% CI) % ORa (95% CI)
Normal 4028 14.7 1.0 5.4 1.0 2.1 1.0 7.7 1.0 3.0 1.0
CIN1 114 28.1 1.2 (0.7-1.9) 14.0 1.3 (0.7-2.4) 0.9 0.2 (0.03-1.9) 12.3 0.9 (0.5-1.7) 7.0 1.8 (0.8-4.0)
CIN2 27 74.1 7.8 (3.2-19.1) 44.4 6.2 (2.7-14.1) 11.1 3.1 (0.8-11.3) 29.6 2.5 (1.0-6.0) 11.1 2.4 (0.7-8.8)
≥CIN3 42 52.4 2.7 (1.4-5.2) 47.6 6.7 (3.4-13.2) 0.0 n/a 4.8 0.3 (0.1-1.2) 4.8 0.9 (0.2-3.8)
aOR: adjusted for age, geographic site and HPV DNA positivity.
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observed in Mongolia (6.3% vs. 23%, 2.1% vs. 19.6%)
[24]. HPV 16 seroprevalence is at similar levels to that
in these five areas of China and Busan, South Korea
(6.3% vs. 6.3%), whereas anti-HPV 18 was less prevalent
than in South Korea (2.1% vs. 9.0%) [25]. The seropreva-
lence data reported here is consistent with HPV geno-
typing data showing that HPV 16 is the dominant type
measured by DNA in cervical samples in China [26,27].
Seroprevalence of HPV 16 was found consistently to be
more prevalent than HPV 18 in all areas of China. HPV
6 was the most prevalent type found in our study, which
is consistent with other studies showing that HPV 6 is
the most prevalent in cross-sectional studies [28]. Be-
cause HPV 6 is not among the most common types of
HPV detected by DNA cervical samples in China [26],
we speculate a high probability of cumulative exposure
to HPV 6 in China, although the specific reason is un-
known. Some possibilities include higher clearance of
HPV 6 than other types or lower induction or persist-
ence rate of antibody of other HPV types upon their in-
fection. There is evidence that incidence of genital warts
has increased in China in recent years [29,30], of which
HPV 6 accounts for 54.9% [31].
The age trend of HPV seropositivity in our study was
characterized by a peak for anti-HPV seroprevalence to
any type in the late 40s, and a relatively flat curve for in-
dividual HPV types across different age groups. Such
age-specific differences are possibly due to the fact that
HPV seropositivity reflects cumulative exposure, which
is higher among older women. High-risk HPV DNA
prevalence peaks in both the early twenties and early
forties in Chinese women [27] and low-risk HPV DNA
generally has a very low prevalence in China. Peak HPV
seroprevalence appeared after the second peak of DNA
prevalence among Chinese women. It has been previ-
ously hypothesized that HPV viral load and persistence
are the two most important predictors for HPV serocon-
version [32]. The sudden decline in seroprevalence in
women in their late forties, which has also been reported
in other studies [23,33-35], might be due to waning im-
mune response in older people or relatively lower expos-
ure rates indicative of a cohort effect. Age-specific
trends in HPV 16/18 seroprevalence were characterized
by a steady increase trend across age, as compared to
that in Mongolia [24], Thailand [34], Taiwan [23], and
Costa Rica [35] where HPV 16/18 seroprevalence was
relatively constant across age. Of note, the age range in
which HPV 16 seroprevalence peaked in China was
much later than in US (45-49 vs. 25-29), similar for
HPV types 6, 11, and 18 [28]. Overall, age-specific sero-
prevalence in China showed similar trend to other areas,
with steady increases with age.
The association with HPV seropositivity and the subse-
quent risk of cervical neoplasia and cervical cancer
remains inconsistent in natural history studies. However,
several studies have shown positive associations between
HPV seropositivity and cervical precancerous lesions
[36-38]. Very few studies have reported a relationship
between HPV seropositivity and the relative grade of cer-
vical lesions. HPV seropositivity stratified by pathology
diagnosis in our study showed that serological response
to HPV 16 antigen was higher among women with CIN2
or above, but not among women with CIN1. This is
likely due to the fact that persistent infection of HPV 16
is a prerequisite to the development of high-grade pre-
cancer or cancer. A higher increased risk of CIN3/cancer
or CIN2/3 was found for both HPV 16 and 18 in Costa
Rica [35] or in America [39], but not in the Czech Re-
public (CIN2/3) [40]. In contrast to HPV 16, HPV 18
seropositivity was not associated with a higher risk of
CIN2/3 in our study, possibly due to the relatively low
observed HPV 18 seroprevalence. Seropositivity for HPV
11 was significantly higher in women with HSIL or
greater ascertained cytology (OR= 4.1; 95% CI: 1.7-10.1,
P< 0.001), but not by pathology diagnoses. This may be
due to low HPV 11 seroprevalence or misclassified cyto-
logical diagnoses. Three of eight anti-HPV 11-positive
patients with high grade cytology were diagnosed as nor-
mal or CIN1 by pathology. A similar pattern was not
seen for anti-HPV 18 or 6.
Seroprevalence among virgins was low though detect-
able (0.6%), as compared to other studies which have
reported a range from 0-3% of HPV 16 [33,41,42]. Given
that HPV can be acquired at other non-genital sites,
these findings may reflect possible non-intercourse sex-
ual transmission [43]. Further, sexual activity was self-
reported by virgins in our survey, and therefore caution
should be taken when interpreting these results. Women
reporting a greater number of sexual partners have been
found to have higher seroprevalence of HPV 16 [15,44-
46], 18 [46], and 11 [46], with many studies reporting a
linear trend [15,45,46]. Among sexually active women in
our study, there was no linear association with the per-
centage of seropositive samples and increasing number
of reported sexual partners for any HPV type. Seroposi-
tivity to HPV 6 or 16 increased sharply from one to two
partners, and slowly reached the plateau at more than
four partners. This plateau phenomenon was also
observed in a study from Norway [47], in which plateau
of HPV seropositivity was reached at three or more
partners.
The “male factor” is an important source of cumulative
exposure of HPV to women. Though reports of hus-
bands’ extramarital relationship were provided by wives
via questionnaire and might be inaccurate, associations
between HPV seropositivity and husbands’ sexual activity
were still observed when husbands were reported to
have extramarital sexual relationships. Induced abortion
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might be a marker of a greater number of pregnancies
or number of lifetime sexual partners, thus explaining its
association with higher anti-HPV 16 levels, results of
which are consistent with a Mongolian study [24]. Edu-
cation level, smoking, drinking, pregnancy history, age at
first menstruation or first sexual intercourse, and contra-
ceptive use had no impact on seropositivity in our study,
agreeing with the findings of several other studies
[24,35,47], but not all [25].
The multiplexed Luminex immunoassay can simultan-
eously quantitate neutralizing antibodies to multiple
HPV types in a large sample size, which is suitable for
our study design [18]. Cross-reactivity between HPV 6
and HPV 11 cannot be ruled out due to many conserva-
tive sequences shared by these two HPV types [18].
Nevertheless, seroreactivity appears to be generally type-
specific as the seroprevalence of HPV 6 was much
higher than other three types. A previous Seattle cohort
study of university women found a higher seroconver-
sion rate for HPV 6 than HPV 16 or 18 or 11 or 45, fol-
lowing detection of the same or different type of HPV
DNA [48,49]. Considering time to seroconversion and
antibody persistence, seroconversion to HPV 6 occurred
earlier with same-type DNA detection than HPV 16,
whereas anti-HPV 6 was not as persistent as anti-HPV
16 or 18 [48,49]. Carter et al [48]. studied HPV 16 and
18 antibody response following incident infections over
years and found out that women in whom HPV DNA
was detected at several visits may be significantly more
likely to seroconvert than are women with only one
HPV DNA-positive visit. Multiple HPV seropositivity in
our study is not high between HPV 6 and 11 (1.3%) or
16 and 18 (0.6%) among sexually active women. On the
other hand, no multiple seropositivity between HPV 6
and 16 or 18 and 16 was observed in women with a
pathological grading of CIN3 or above, whereas the only
two women seropositive for HPV 11 with CIN3 or above
were also positive for anti-HPV 16. It might be because
serum antibody response is a marker of lifetime cumula-
tive exposure and some cross protection between types
might exist [50]. However, lack of infection and serocon-
version history over time in this cross-sectional study
cannot reinforce explanation of cross protection between
specific types.
The strength of our study is that it was a multi-center
study with a large sample size. The study covered five
sites across China, including both rural and urban areas.
We also included women with a wide age range from 15
to 54, stratified into five-year age groups. The number of
virgins we recruited was also relatively large, providing
source data for future planning of a vaccination pro-
gram. Also, both the DNA and serology test used in this
study are well validated and standardized. Among study
limitations, data obtained from the five geographic sites
might not be representative of the entire nation of
China, particularly given the variation of HPV seroposi-
tivity across the sites or age groups. Also, women were
recruited through posters or advertisement, but not by
random sampling, indicating possible selection bias in
our study. This bias is, to some extent, offset by the rela-
tively large sample size, wide age range of participating
women, as well as the inclusion of multiple geographical
sites. Self-reported sexual behavior and their husbands’
extramarital sexual behavior by female subjects may also
have introduced some bias.
Conclusions
Seroprevalence of HPV 6/11/16/18 among sexually ac-
tive women or virgins in China was not systematically
investigated prior to this study. HPV seroprevalence pro-
vided a picture of cumulative exposure to HPV over a
certain period, rather than cross-sectional transient ex-
posure that could be measured by HPV DNA detection.
Our findings can be used for design and implementation
of cervical cancer control and prevention programs via
future prophylactic vaccination programs, in regards to
regional and age distribution of immunological
responses to these four HPV types. HPV seroprevalence
is relatively low and varies by region in China. There is
constant exposure to HPV infection, particularly HPV 6
or 16, among women at age of 20 or above, and the
chance of exposure increases with age. For optimal pub-
lic health benefits in China, vaccination programs should
target young women prior to their becoming sexually ac-
tive and the potential exposure to HPVs. Virgins in our
study with median age of 18 showed significantly lower
HPV seroprevalence, compared with sexually active
women. We therefore suggested girls in the age range of
14 to 18, primarily junior or senior high school students,
to be targeted for vaccination programs. Approximately
half of women with a pathology grading of CIN3 or
above were seropositive for HPV 6/11/16/18 in our
study. We presumed prevention of about 50% of CIN3/
cancer can be accounted for if prophylactic vaccination
of these four types can be successfully implemented.
These data on population-based HPV seroprevalence in
representative samples of women throughout China can
be used as baseline data to assess future changes in sero-
prevalence over time. These data will be particularly im-
portant in the context of future evaluation of HPV
prophylactic vaccines as they become more accessible
and utilized in China.
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